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Abstract
Background: The Wnt family of secreted proteins is implicated in the regulation of cell fate during
development, as well as in cell proliferation, morphology, and migration. Aberrant activation of the
Wnt/β-catenin signaling pathway leads to the development of several human cancers, including
breast cancer. Secreted frizzled-related protein 1 (SFRP1) antagonizes this pathway by competing
with the Frizzled receptor for Wnt ligands resulting in an attenuation of the signal transduction
cascade. Loss of SFRP1 expression is observed in breast cancer, along with several other cancers,
and is associated with poor patient prognosis. However, it is not clear whether the loss of SFRP1
expression predisposes the mammary gland to tumorigenesis.
Results: When SFRP1 is knocked down in a non-malignant immortalized mammary epithelial cell
line (76 N TERT), nuclear levels of β-catenin rise and the Wnt pathway is stimulated. The SFRP1
knockdown cells exhibit increased expression of the pro-proliferative Cyclin D1 gene and
increased cellular proliferation, undergo a partial epithelial-mesenchymal transition (EMT), are
resistant to anchorage-independent cell death, exhibit increased migration, are significantly more
invasive, and exhibit a CD24low/CD44high cell surface marker expression pattern.
Conclusion:  Our study suggests that loss of SFRP1 allows non-malignant cells to acquire
characteristics associated with breast cancer cells.
Background
The most frequently occurring cancer in women, and the
second leading cause of cancer death among women, is
breast cancer. Cancer results from cellular mutations that
enhance proliferation, decrease anti-proliferative signals,
and decrease programmed cell death; and from cellular
alterations that enhance angiogenesis and metastasis [1].
Members of the Wnt family of secreted proteins regulate
cellular proliferation, morphology, and migration by way
of  β-catenin-mediated transcriptional activation [2-4].
Inappropriate activation of the Wnt/β-catenin pathway,
which results from mutations in several downstream
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genes, contributes to the genesis of a wide range of human
cancers [2]. However, such mutations are rarely observed
in breast cancer despite the finding that β-catenin is stabi-
lized in a majority of human breast tumors [5]. In addi-
tion, aberrantly activated Wnt signaling leads to
inappropriate mammary gland development and mam-
mary tumorigenesis in mice [3].
The Wnt family of secreted proteins is implicated in the
regulation of cell fate during development, as well as in
cell proliferation, morphology, and migration [2-4]. The
best characterized Wnt pathway is the canonical Wnt/β-
catenin pathway whereby Wnt signaling leads to the stabi-
lization of β-catenin and activation of β-catenin-respon-
sive gene expression. Wnt ligands activate the Wnt/β-
catenin signaling pathway by binding to receptors com-
prised of Frizzled proteins in conjunction with one of the
LDL receptor-related proteins LRP5 or LRP6. Receptor
activation results in the ability of a cytoplasmic protein,
Dishevelled (Dsh), to inhibit a multiprotein complex that
includes APC, Axin, and the kinase GSK3β. Under normal
circumstances, this complex is responsible for degrading
the free cytosolic pool of β-catenin via phosphorylation of
specific serine and threonine residues on the N-terminal,
which ultimately targets the protein for ubiquitination
and proteolysis. When this complex is dissociated as a
result of Wnt signaling, β-catenin is less efficiently phos-
phorylated and ubiquitinated, which leads to increase
nuclear β-catenin levels. In the nucleus, β-catenin forms a
complex with the TCF/LEF1 family of HMG box transcrip-
tion factors and stimulates the expression of specific target
genes including the cyclin D1 oncogene.
Secreted frizzled-related proteins (SFRPs) are a family of
Wnt antagonists which contain a cysteine-rich domain
that is homologous to the Wnt-binding domain of friz-
zled receptor proteins [6]. However, SFRPs do not contain
a transmembrane domain and therefore reside in the
extracellular compartment where they antagonize Wnt
signaling by binding to Wnt ligands and prevent ligand-
receptor interactions and signal transduction [7]. Loss of
SFRP expression is found in a multitude of cancers includ-
ing breast cancer [8-10], cervical cancer [11], hepatocellu-
lar cancer [12], urothelial cancer [13], head and neck
squamous cell cancer [14], lymphocytic leukemia [15],
lung cancer [16], neuroectodermal cancer [17], bladder
cancer [17], ovarian cancer [18], mesothelioma [19],
endometrial cancer [20], and cervical cancer [11].
SFRP1 is a member of this protein family that is signifi-
cantly downregulated in breast tumors and in breast carci-
noma cell lines [8,9]. Moreover, loss of SFRP1 expression
is associated with poor overall survival in patients with
early breast cancer [10]. The loss of SFRP1 expression
occurs both at the RNA level as demonstrated by in situ
hybridization [21] and at the protein level as shown by
immunohistochemistry [10]. Recent data have revealed
that like many of the cancers described above, promoter
hypermethylation is the reason for loss of SFRP1 mRNA
and protein expression [22,23].
Currently, it is unknown whether SFRP1 loss causes the
mammary gland to be predisposed to breast cancer devel-
opment. This work was initiated to investigate whether
loss of SFRP1 expression renders mammary epithelial
cells susceptible to transformation in vitro. We demon-
strate that when SFRP1 is downregulated in a non-malig-
nant immortalized mammary epithelial cell line,
sensitivity to Wnt signaling is enhanced and the cells
exhibit distinct hallmarks of cancer progression.
Results
Characterization of 76 N TERT cells stably transfected 
with siSFRP1
To evaluate the effects of SFRP1 down-regulation in an
immortal mammary epithelial cell line, 76 N TERT cells
were stably transfected with the pSUPER-siSFRP1 con-
struct. To confirm that the expression level of SFRP1 was
knocked down in siSFRP1 transfected cells, total RNA was
isolated from vector transfected 76 N TERT cells (TERT-
pSUPER) and siSFRP1 transfected cells (TERT-siSFRP1).
Real-time PCR analysis revealed that the mRNA expres-
sion levels of SFRP1 are significantly lower in TERT-
siSFRP1 cells when compared with TERT-pSUPER cells
(Figure 1A). Additionally, to confirm that TERT-siSFRP1
cells secrete lower levels of SFRP1 protein, supernatants
were collected from TERT-pSUPER and TERT-siSFRP1
cells and subjected to western blot analysis. Indeed, there
is less SFRP1 protein in the media collected from TERT-
siSFRP1 cells (Figure 1B).
Evaluation of Wnt/β-catenin signaling in TERT-siSFRP1 
cells
Considering that SFRP1 antagonizes the Wnt/β-catenin
pathway, we next sought to determine whether reduced
levels of SFRP1 would activate β-catenin signaling. Trans-
location of β-catenin from the cytoplasm to the nucleus is
a strong indication that Wnt signaling is upregulated.
TERT-pSUPER and TERT-siSFRP1 cells were grown on cov-
erslips for 24 hours and phase contrast images illustrate
the apparent morphology differences between the two cell
lines (Figure 2A). The phenotypic changes observed when
SFRP1 is knocked-down in 76 N TERT cells include a loss
of cell polarity causing a spindle-cell morphology and an
increase in the formation of pseudopodia. Moreover, flu-
orescent immunocytochemistry revealed that the mor-
phological changes observed in TERT-siSFRP1 cells are
accompanied by a marked decrease in cytoplasmic β-cat-
enin protein expression levels along with a concomitant
increase in nuclear β-catenin accumulation (Figure 2A).Cancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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The nuclei were labeled with with 4', 6-diamidino-2-phe-
nylidole to confirm that the cellular localization of β-cat-
enin was indeed nuclear in TERT-siSFRP1 cells.
Given that β-catenin accumulates in the nucleus of TERT-
siSFRP1 cells, we tested the hypothesis that there would
be an increase in β-catenin-mediated transcription. TERT-
pSUPER and TERT-siSFRP1 cells were grown in either con-
trol medium or Wnt3a medium and transfected with
Super8XTOPflash (a β-catenin driven firefly luciferase
reporter vector) or Super8XFOPflash (a firefly luciferase
reporter vector that has a point mutation in the β-catenin
response element rendering the construct unresponsive to
β-catenin activity) [24]. Twenty-four hours after transfec-
tion, luciferase activity was measured and we found that
TERT-siSFRP1 cells exhibit a significant increase in relative
luciferase activity when grown in the presence of the
Wnt3a ligand (Figure 2B; F = 97.58(1,12), P < 0.0001).
CyclinD1 is a well characterized downstream gene of
Wnt/β-catenin signaling that is upregulated in response to
β-catenin transcriptional activation. Therefore, we sought
to determine whether in the presence of Wnt3a stimulated
β-catenin activation, Cyclin D1 expression would be
higher in TERT-siSFRP1 cells when compared with TERT-
pSUPER cells. Cells were seeded and allowed to attach
overnight. The media was then changed to either control
media or Wnt3a media and total RNA was isolated 24
hours after the treatment media was added. Real-time
PCR studies confirmed that Cyclin D1 mRNA levels are
significantly higher when TERT-siSFRP1 cells are grown in
Wnt3a media (Figure 2C; F(1,8) = 8.16, P = 0.0213).
The relative expression levels of SFRP1 mRNA and protein are reduced in TERT-siSFRP1 cells Figure 1
The relative expression levels of SFRP1 mRNA and protein are reduced in TERT-siSFRP1 cells. A, Total RNA 
was isolated from each cell line for real-time PCR analysis. The level of SFRP1 mRNA was normalized to amplification of 
GAPDH mRNA, which was performed in parallel wells for each cell line. Bars represent mean ± SEM SFRP1/GAPDH and are 
expressed as relative expression of TERT-PSUPER cells. ***p < 0.001 (significantly different from TERT-pSUPER cell line using 
student's t-test). B, The proteins from TERT-pSUPER and TERT-siSFRP1 supernatants were collected, concentrated, and 
SFRP1 expression was assessed by Western Blot Analysis. Twenty-five ng of recombinant SFRP1 was loaded onto the gel to 
confirm SFRP1 band size and specificity.Cancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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Considering that an increase in Cyclin D1 expression is
associated with an increase in cellular proliferation, our
goal was to establish whether there was an associated
increase in proliferation in TERT-siSFRP1 cells when com-
pared with TERT-pSUPER cells. Cells were seeded,
allowed to attach overnight, and the following day both
cell lines were treated with 3H-Thymidine in either control
media or Wnt3a media. The cells were lysed 24 hours later
and total cpm was measured. The data obtained from 3H-
Thymidine assays confirmed that TERT-siSFRP1 cells pro-
liferate significantly more rapidly (Figure 2D; F(1,32) =
20.62, P < 0.0001).
Loss of SFRP1 results in an increase in Wnt-mediated β-catenin activity Figure 2
Loss of SFRP1 results in an increase in Wnt-mediated β-catenin activity. A, TERT-pSUPER and TERT-siSFRP1 cells 
were immunostained with anti-β-catenin and counterstained with DAPI phase contrast images were captured at 20× magnifica-
tion (scale bar 100 μm) and fluorescent images were captured at 40× magnification (scale bar 50 μm). B, TERT-pSUPER and 
TERT-siSFRP1 cells were transfected with either the Super8XTOPflash or Super8XFOPflash vectors and relative luciferase 
activity was measured after an overnight incubation in the presence or absence of the Wnt3a ligand. Bars represent mean ± 
SEM of relative luciferase activity (firefly luciferase activity/renilla luciferase activity) normalized to the relative luciferase activity 
in TERT-pSUPER cells treated with control media. C, Twenty-four hours after the cells were treated with either control 
medium or Wnt3a medium, total RNA was isolated for real-time PCR analysis. The level of Cyclin D1 mRNA was normalized 
to amplification of GAPDH mRNA, which was performed in parallel wells for each treatment. D, Twenty-four hours after the 
cells were treated with 3H-Thymidine in either control media or Wnt3a media, the cells were lysed and total cpm was meas-
ured. Experiments were performed in at least triplicate wells and bars represent mean ± SEM cpm. *p < 0.05, ***p < 0.001 [sig-
nificantly different from corresponding TERT-pSUPER cell line using Bonferoni's t-test following two-way ANOVA].Cancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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Evaluation of EMT associated gene expression in TERT-
siSFRP1 cells
Epithelial-mesenchymal transitions (EMTs) are implicated
in the conversion of early stage tumors into invasive malig-
nancies. EMT is a process whereby epithelial cells lose
polarity as well as cell-cell contacts and undergo a dramatic
remodeling of the cytoskeleton resulting in a mesenchymal
morphology. TERT-siSFRP1 cells appear to exhibit this phe-
notype exemplified by a switch from a polarized, epithelial
phenotype to a more motile fibroblastoid phenotype.
Down-regulation of E-cadherin, a central component of
cell-cell adhesion junctions, is a hallmark of EMT. Both
immunocytochemistry as well as real-time PCR analyses
reveal that E-cadherin expression is significantly repressed
in TERT-siSFRP1 cells (Figure 3A–B). In addition to the loss
of E-cadherin expression, EMT is characterized by the
acquisition of the mesenchymal marker vimentin. Vimen-
tin is a type-III intermediate filament that is typically
expressed in mesenchymal cells and it is only expressed in
epithelial cells when they become involved in physiologi-
cal or pathological processes requiring epithelial cell migra-
tion [25]. Immunocytochemistry and real-time PCR
analyses demonstrate that vimentin is significantly upregu-
lated in TERT-siSFRP1 cells (Figure 3A–B).
We next sought to determine whether key regulators of E-
cadherin and vimentin expression are altered in TERT-
siSFRP1 cells. Although the E-cadherin repressors Snail
and Slug are modestly increased in TERT-siSFRP1 cells
(data not shown), both ZEB1 (also known as TCF8 and
δEF1) and ZEB2 (also known as ZFXH1B and SMAD-
interacting protein 1 [SIP1]) are significantly increased in
response to SFRP1 down-regulation (~40 fold and ~100
fold respectively, Figure 3B). These two E-box-binding
transcription factors are important regulators in the com-
plex network of transcriptional repressors that regulate the
expression of E-cadherin and EMT through the repression
of a number of master regulators of epithelial polarity [26-
29].
Next, in order to confirm that observed EMT associated
morphological changes in TERT-siSFRP1 cells are due to
SFRP1 loss and not due to off-target siRNA effects, SFRP1
was re-expressed in these cells. Real-time PCR analysis was
utilized to confirm that SFRP1 expression is up-regulated
in TERT-siSFRP1 cells (TERT-siSFRP1+SFRP1). In addi-
tion, we are able to show that the expression of E-cadherin
is elevated and that the levels of vimentin, ZEB1, and
ZEB2 are reduced in TERT-siSFRP1+SFRP1 cells when
compared with TERT-siSFRP1 cells indicating that they are
direct SFRP1 targets (Figure 3C).
Evaluation of the cellular characteristics exhibited by 
TERT-siSFRP1 cells
Considering that cells that have undergone EMT are more
likely to metastasize, we next sought to measure the
migratory and invasive properties of TERT-siSFRP1 cells.
First, a simple scratch wound assay revealed that after just
8 hours, TERT-siSFRP1 cells are more motile then TERT-
pSUPER cells (Figure 4A). Next, the cells were plated in
BD BioCoat™ control chambers or Matrigel™ Invasion
Chambers (BD Biosciences) and the cells capable of
migrating through the 8 μm pore (migration) or through
Matrigel™ (invasion) towards a chemoattractant were
stained with 10% crystal violet and quantified. We clearly
show that TERT-siSFRP1 cells are significantly more
migratory and invasive then TERT-pSUPER cells (Figure
4B).
Normal adherent cells are strongly dependent on adhe-
sion to extracellular matrix for cell proliferation and
undergo apoptosis if they are detached from the substra-
tum, in a process known as anoikis [30]. In contrast,
tumor cells can survive and grow without adhesion to a
substratum; this is a critical step in tumorigenic transfor-
mation [30,31]. Cells were grown in anchorage-independ-
ent conditions and flow cytometry analysis showed that
TERT-siSFRP1 cells are significantly more resistant to
anoikis (Figure 5A).
Human metastatic breast cancer cell lines have a higher
percentage of CD44high/CD24low cells than less aggressive
breast cancer cells lines [32]. Moreover, Mani et. al.
recently showed that non-malignant mammary epithelial
cells that have been induced to undergo EMT exhibit a
CD44high/CD24low cell surface marker expression pattern
[33]. Figure 5B illustrates that TERT-siSFRP1 exhibit a
striking population shift to a CD44high/CD24low pheno-
type compared with TERT-pSUPER cells (which exhibit a
CD44low/CD24high  phenotype). Interestingly, this
CD44high/CD24low cell surface maker expression pattern is
associated with both human breast cancer stem cells and
normal mammary epithelial progenitor cells [34].
Genetic profile of TERT-siSFRP1 cells
To determine how SFRP1 loss affects additional different
cellular processes, we performed a microarray analysis of
TERT-siSFRP1 cells compared with TERT-pSUPER cells.
One class SAM analysis identified 130 genes that were dif-
ferentially regulated in SFRP1 knockdown cells (FDR =
4.7%). These genes, along with their average fold change
relative to the parent are listed in Additional file 1. Inge-
nuity pathway analysis indicated that regulation of Cell
Death (p = 3.99e-4 to 4.99e-2) was an important molecu-
lar and cellular function, with the following pro-survival
genes being upregulated: MDM2, TMSB4X, ATRX, CCL25,
and APH1A. These same genes play an important role in
Cell-to-Cell Signaling and Interaction (p = 1.03e-3 =
4.33e-2) and Cellular Assembly and Organization (p =
1.46e-3 – 4.75e-2), and these categories were also signifi-
cant in Ingenuity Pathway Analyses. MDM2 is an E3 ligase
that is responsible for the ubiquination and subsequentCancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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TERT-siSFRP1 cells exhibit a gene expression profile that is consistent with partial EMT Figure 3
TERT-siSFRP1 cells exhibit a gene expression profile that is consistent with partial EMT. A, TERT-pSUPER and 
TERT-siSFRP1 were immunostained with either anti-E-cadherin or anti- vimentin and counterstained with DAPI. B, For each 
cell line, total RNA was isolated from three separate harvests for real-time PCR analysis of E-Cadherin, vimentin, ZEB1 and 
ZEB2. C, The SFRP1-pCDNA3.1 construct was transfected into TERT-siSFRP1 cells and RNA was isolated from 3 separate 
harvests. Real-time PCR analysis was performed to measure the relative expression of SFRP1, E-cadherin, vimentin, ZEB1 and 
ZEB2. All Real-time PCR results are from two separate experiments performed in triplicate and results were normalized to 
amplification of GAPDH mRNA. Bars represent mean ± SEM and are expressed as fold change with respect to TERT-pSUPER 
cells. *p < 0.05 ***p < 0.001 (significantly different from TERT-pSUPER cell line using student's t-test), ‡p < 0.001 (significantly 
different from TERT-siSFRP1 cell line using Bonferoni's t-test following one-way ANOVA). Immunostain images were captured 
at 40× magnification (scale bar 50 μm).Cancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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Loss of SFRP1 increases the migratory and invasive behavior of 76 N TERT cells Figure 4
Loss of SFRP1 increases the migratory and invasive behavior of 76 N TERT cells. A, TERT-pSUPER and TERT-
siSFRP1 cells were plated in 30 mm dishes and allowed to reach 100% confluence. A pipette tip was utilized to generate a 
wound (scratch) down the center of the plate. Image of the cells capable of migrating across the scratch 8 hours after the 
wound was created. Images were captured at 20× magnification; scale bar 100 μm. B, TERT-pSUPER and TERT-siSFRP1 cells 
that were plated in BD BioCoat™ control inserts or Matrigel™ invasion chambers and the cells capable of migrating through 
the 8 μm pore or invading the reconstituted basement membrane (Matrigel™) through the 8 μm pore towards a chemoat-
tractant were stained with 10% crystal violet and counted. Images were captured at 10× magnification; scale bar 500 μm. 
(Experiments were repeated three times and the number of cells within a representative 10× field from each experiment were 
counted and bars represent mean ± SEM cell number. *p < 0.05,***p < 0.001 (significantly different from TERT-pSUPER cells 
using a student's t-test).Cancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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degradation of the p53 tumor suppressor gene [35].
TMSB4X encodes an actin sequestering protein which is
involved in angiogenesis, cell proliferation, migration,
and differentiation [36,37]. The protein encoded by ATRX
gene contains an ATPase/helicase domain and belongs to
the SWI/SNF family of chromatin remodeling proteins.
Mutations in this gene lead to mental retardation which
may be explained by the finding that ATRX is involved in
neuronal cell survival [38]. The cytokine encoded by
CCL25 has chemotactic activity which has been shown to
enhance the migration of several cell types including mes-
enchymal stem cells [39]. Finally, APH1A is a multipass
transmembrane protein that interacts with presenilin and
nicastrin as a functional component of the gamma-secre-
TERT-siSFRP1 cells are anoikis resistant and exhibit CD44high/CD24low cell surface marker expression pattern Figure 5
TERT-siSFRP1 cells are anoikis resistant and exhibit CD44high/CD24low cell surface marker expression pattern. 
A, Cell culture dishes were coated with 1% agarose/DMEM, which was allowed to polymerize creating a barrier that prevented 
cellular attachment. TERT-pSUPER and TERT-siSFRP1 cells were plated in the wells and after 24 hours, FACs analysis was per-
formed to compare the percentage of propidium iodide positive (FL2; dead cells) between cell lines. Scatter plot depicting FL2 
positive cells vs. forward scatter (FSC-H) and oval represents area of viable cell not included in the analysis. Two separate 
experiments were performed in triplicate and bars represent mean ± SEM percent cell death. ***p < 0.001 (significantly differ-
ent from control TERT-pSUPER cells using student's t-test) B, TERT-pSUPER and TERT-siSFRP1 cells were incubated with anti-
bodies against human CD44-FITC and CD24-PE and labeled cells were analyzed by flow cytometry. FACS analysis reveals that 
TERT-pSUPER cells have a CD44low/CD24high phenotype and TERT-siSFRP1 cells exhibit a CD44high/CD24low phenotype.Cancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
Page 9 of 15
(page number not for citation purposes)
tase complex which is required for the intramembrane
proteolysis of Notch [40] and activation of this signaling
pathway is associated with mammary oncogenesis [41].
Discussion
The present study indicates that a reduction in SFRP1
expression allows 76 N TERT cells to acquire many of the
properties observed in breast cancer cells. These SFRP1
knocked down cells (TERT-siSFRP1) have increased levels
of β-catenin in their nucleus, which is indicative of β-cat-
enin stabilization and activated Wnt/β-catenin signaling.
Moreover, TERT-siSFRP1 cells undergo a dramatic pheno-
typic change which can be explained in part by a geno-
typic change that is consistent with EMT. Similar to
malignant mammary cells, TERT-siSFRP1 cells are more
resistant to anchorage-independent cell death, are quite
migratory and invasive, and exhibit a CD44high/CD24low
cell surface marker expression pattern. Finally, microarray
analysis revealed that the characteristics exhibited by
TERT-siSFRP1 are consistent with affected pathways
including cell death, cell-to-cell signaling, and interaction
cellular assembly.
The downstream effector of Wnt signaling, β-catenin,
exists in three different subcellular forms: membrane-
bound (complexed with E-cadherin), cytosolic, and
nuclear [42]. The data presented here show that β-catenin
accumulates in the nucleus of TERT-siSFRP1 cells where it
is available to act as a transcription factor. Considering
that genes regulated by β-catenin are involved in tumori-
genesis, the nuclear accumulation of β-catenin may be a
possible mechanism by which SFRP1 renders the mam-
mary gland more susceptible to tumorigenesis. Interest-
ingly, Nakopoulou et. al. have demonstrated that
increased nuclear staining for phospho-β-catenin in
breast tumor specimens is associated with poorer overall
survival (OS)[43]. Similarly, Veeck et. al. have found
increased promoter hypermethylation of SFRP1 is also
associated with poor prognosis [23]. Putatively, SFRP1
loss may be associated with nuclear β-catenin accumula-
tion in human breast tumors. Interestingly, β-catenin-
mediated transcription from an exogenous reporter con-
struct was not activated unless exogenous Wnt3a was
added to the media. These findings suggest that either
greater amounts of nuclear β-catenin are necessary to see
significant differences in reporter activity or that SFRP1
loss is affecting alternate pathways through either non-
canonical Wnt signaling or Wnt-independent mecha-
nisms.
Previously, Shulewitz et. al. ultilized siRNA oligonucle-
otides to transiently silence SFRP1 MCF-10A breast epi-
thelial cells. In order to evaluate the permanent changes in
cellular behavior that occur in response to SFRP1 down-
regulation, we chose to create the TERT-siSFRP1 stable cell
line to [44]. Our results are consistent with Shulewitz et.
al. in that TERT-siSFRP1 cells exhibit an increase in β-cat-
enin-mediated luciferase activity and CyclinD1 expression
in response to Wnt3a stimulation. CyclinD1 is a cell-cycle
regulator essential for G1 phase progression [45] and the
pro-proliferative nature of this oncogene is implicated in
pathogenesis of several human tumor types, including
breast carcinomas [46]. Our findings clearly demonstrate
that the increase in Cyclin D1 expression, due to aberrant
β-catenin transcriptional activation, observed in TERT-
siSFRP1 cells contributes to an increase in cellular prolif-
eration. However, other proliferative cues must be
affected by SFRP1 loss because the enhanced cellular pro-
liferation occurs both in the presence as well as the
absence of the Wnt3a ligand whereas Cyclin D1 expres-
sion is increased only when Wnt3a is added to TERT-
siSFRP1 cells.
Tumor cell metastasis occurs when primary epithelial cells
exit their site of origin and colonize at a distant site. In
order for this process to occur, the cells must invade the
extracellular matrix, migrate into blood vessels, and
invade secondary organs. Here we show that when SFRP1
is down-regulated, 76 N TERT cells become significantly
more migratory as well as invasive. The phenotypic
changes observed when SFRP1 is down-regulated include
a transformation from an epithelial cell morphology to a
more fibroblast-like cell with reduced intercellular adhe-
sion and increased motility. Interestingly, these character-
istics define the EMT process, which is known to occur
during tumor progression as well as metastasis. After care-
ful assessment of several genes implicated in EMT, we can
conclude that loss of SFRP1 expression likely pushes 76 N
TERT cells into this pathophysiological transformation.
E-cadherin down-regulation is frequently associated with
Wnt signaling and we show here that E-cadherin is signif-
icantly repressed in TERT-siSFRP1 cells. Loss of E-cadherin
expression is emerging as one of the most common indi-
cators of EMT onset, as it normally acts as a tumor sup-
pressor by inhibiting invasion [47,48]. Considering that
both ZEB1 and ZEB2 are key transcriptional repressors of
E-cadherin, and the expression levels of ZEB1 and ZEB2
are drastically enhanced in response to SFRP1 down-regu-
lation, it is reasonable to suspect that the loss in E-cad-
herin expression is a direct result of the increase in these
transcription factors. The expression of vimentin is also
frequently associated with the EMT process and is signifi-
cantly upregulated in TERT-siSFRP1 cells. The increase in
vimentin expression may be due to the ~100-fold increase
in ZEB2 expression, as ZEB2 is also involved in up-regu-
lating the expression of vimentin in breast cancer cells
[49]. Interestingly, Gilles et. al. have shown that β-cateninCancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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can transactivate vimentin expression which could
explain, in part, the increase in vimentin expression when
SFRP1 is down-regulated [50].
It is well established that de-regulated expression and
altered function of the genes involved in cell-cycle regula-
tion and death contribute to the pathogenesis of cancer
[51] and SFRP1 exhibits an apoptotic function in several
different tissues, including breast epithelial cells [52-54].
However, the data presented here are the first to show that
SFRP1 down regulation renders mammary epithelial cells
resistant to cell death. Moreover, this characteristic is
observed in anchorage-independent growth conditions
and in the absence of exogenous Wnt3A ligand. Interest-
ingly, caspase-1 is significantly down-regulated in TERT-
siSFRP1 cells (data not shown). Although the role of cas-
pase-1 down regulation has not been studied in breast can-
cer cells, it is lost in other cancer cell lines [55,56]. The
microarray data provide some other suggestions as to how
TERT-siSFRP1 cells become resistant to anoikis, such as the
increase in the pro-survival gene, Mdm-2, which is a potent
regulator of p53. We also noted an increase in ATRX, a
member of the SWI/SNF family of chromatin remodeling
proteins, which has been previously shown to be involved
in neuronal cell survival [38]. However, further work is
required to fully elucidate the mechanisms by which SFRP1
loss increases anchorage independent cell survival.
Metastatic breast cancer cells are often characterized by a
CD44high/CD24low cell surface marker expression pattern
[32]. Although it is logical that cells that have undergone
EMT and exhibit this cell surface marker expression pat-
tern are able to break out from the primary tumor and
metastasize to distant locations, it has remained poorly
understood as to how such cells could self-renew to form
secondary metastases. Recent work by Mani et al. has
addressed this dilemma by genetically modifying non-
malignant mammary epithelial cells to undergo EMT [33].
Not surprisingly, these cells were shown to exhibit a
CD44high/CD24low phenotype. Although this cell surface
marker expression pattern is associated with metastatic
potential, it is also observed in both normal as well as
breast cancer stem cells [34]. Forced EMT allowed the cells
to exhibit additional characteristics associated with pro-
genitor cells including an increased ability to form pri-
mary as well as secondary mammospheres, differentiate
into secondary structures, and express both luminal and
basal/myoepithelial markers, which exemplifies the bipo-
tency of these cells [33]. We have observed that loss of
SFRP1 also results in primary and secondary mammos-
phere formation (data not shown) and we are currently
investigating whether these cells have additional stem
cell-like characteristics.
It is noteworthy to point out that non-conical Wnt signal-
ing is also known to induce cell migratory phenotypes
during developmentand isoften separated into two sub-
categories including the Planar Cell Polarity (PCP) path-
way and the Wnt/Ca2+ pathway [57]. The EMT associated
phenotype observed in TERT-siSFRP1 cells may be
explained in part by particular sections of the signal trans-
duction cascades that characterize these pathways. First,
PCP signals through Rho and Rac GTPases to alter cell
polarization and affect the actin cytoskeleton resulting in
an increase in cellular motility and directional migration.
Second, the Wnt/Ca2+ pathway can activate the GTPase
CDC42, which forms a complex with Par3 and atypical
protein kinase, and this pathway has been previously
implicated in ErbB2 mediated EMT in mammary epithe-
lial cells [58]. Finally, the up-regulation of TMSB4X, fil-
amin beta, and ADAMTS15 noted in the microarray
analysis support the pro-migratory and invasive features
and hint at the possible role of either other non-canonical
Wnt pathways and/or Wnt-independent EMT mecha-
nisms also being induced by SFRP1 loss [59-61].
The reduction in SFRP1 could potentially alter other path-
ways, independent of Wnt signaling, which could contrib-
ute to a malignant transformation and progenitor cell
phenotype. For instance, Notch signaling may very well be
aberrantly activated in TERT-siSFRP1 cells and exacerbate
their aggressive phenotype. Ayyanan et. al. previously
showed that Wnt-1 treated HMECs undergo a malignant
transformation which is a result of not only activated β-
catenin, but also activated Notch signaling [62,63]. Our
data lends support to the hypothesis that the loss of SFRP1
may facilitate Notch signaling. Specifically, TERT-siSFRP1
cells have increased levels of the APH1A gene, which is a
member of the gamma-secretase complex required for the
intramembrane proteolysis of and activation of Notch.
Furthermore, Mdm-2 is an ubiquitin ligase which targets
the Notch inhibitor, Numb, for degradation [64]. Lastly,
Notch is frequently activated in CD44hi/CD24lo breast
epithelial cells and inhibition of gamma-secretase activity
has been shown to block the ability of the cells to form
mammospheres and sensitizes the cancer cells to undergo
growth arrest and apoptosis [65,66]. Research is ongoing
to determine the importance of Notch signaling in the
physiological characteristics imparted by SFRP1 loss.
Conclusion
The cell line that we have constructed (TERT-siSFRP1) has
allowed us to look at the effects of reduced SFRP1 expres-
sion levels on subcellular localization of β-catenin as well
cellular morphology, characteristics, behaviors, and
genetic profile. This cell line will allow us to pursue future
studies designed to assess the role of SFRP1 loss in tumor-
igenesis. Based on the available information and our find-
ings, we propose that the maintenance of SFRP1
expression is especially important in preventing aberrant
Wnt signaling and inappropriate cell behavior in the
mammary gland. The finding that SFRP1 down-regulationCancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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promotes anoikis resistance, migration as well as inva-
sion, and increases the population of CD44High/CD24low
is quite significant because it may partially explain why
breast tumors with lost SFRP1 expression are associated
with poor patient prognosis.
Methods
Plasmids and Constructs
The SFRP1 siRNA and plasmid was designed to generate
the following RNA target sequence 5'-CUACGUGAGCU-
UCCAGUCG-3' [44]. The siSFRP oligonucleotide
sequences: 5'-
GATCCCCCTACGTGAGCTTCCAGTCGTTCAAGAGAC-
GACTGGAAGCTCACGTAGTTTTTA-3' and 5'-AGCT-
TAAAAA CTACGTGAGCTTCCAGTCGTCTCTTGAA
CGACTGGAAGCTCACGTAGGGG-3' were obtained from
Integrated DNA Technologies (IDT; Coralville, IA) and
annealed in 500 μM RNase-Free Duplex Buffer (IDT) and
heated to 94°C for 2 min. The annealed oligonucleotides
were compatible with and cloned directly into the BglII
and HindIII sites of the pSUPER.retro vector (OligoEn-
gine, Seattle, WA). The SFRP1-pCDNA3.1 construct was
supplied by Dr. Yoshitaka Sekido (Aichi Cancer Center
Research Institute, Nagoya, Japan). Both
Super8xTOPFlash and Super8XFOPflash luciferase vectors
were kindly provided by Dr. Randall Moon (University of
Washington, Seattle, WA) and pRL-CMV was purchased
from Promega (Madison, WI).
Cell Culture
76 N TERT cells were obtained from Dr. Vimla Band and
were routinely cultivated at 37°C in 5% CO2 and main-
tained in DMEM/F12 (GIBCO, Grand Island, NY) and the
following components from GIBCO: 1% FBS, 1× Antibi-
otic-Antimycotic (100×), and 20 μg/mL Gentamycin. The
following components from Sigma (St Louis, MO) were
also used: 50 μM L(+)-Ascorbic acid sodium salt, 1 ng/ml
Cholera Toxin Vibrio, 12.5 ng/ml Epidermal Growth Fac-
tor murine submaxillary, 2 nM β-Estradiol, 0.1 mM Eth-
anolamine, 1 μg/ml Hydrocortisone-Water Soluble, 1 μg/
ml human Insulin solution, 0.1 mM O-Phosphoryleth-
anolamine, 35 μg/ml bovine pituitary extract, 15 nM
Sodium selenite, 10 μg/ml human apo-Transferrin, and
10 nM 3,3',5-Triiodo-L-thyronine sodium salt. 76 N TERT
cells were plated at a density of 1.5 × 106 cells per 10 cm
dish and transfected with 24 μg siSFRP1-PSUPER.retro
using Lipofectamine™2000 (Invitrogen, Carlsbad, CA).
The pSUPER.retro vector was trasfected into 76 N TERT
cells to provide a negative control because the experi-
ments use stably transfected populations, which were
obtained by selection with 2 μg/ml puromycin (Sigma).
To genereate TERTsiSFRP1+SFRP1 cells, TERT-siSFRP1
cells were grown in triplicate (30 mm plates; 5 × 105 cells/
well) and 4 μg of the SFRP1-pCDNA3.1 vector was tran-
siently transfected into the cells. Mouse fibroblasts that
overexpress the Wnt3a ligand (ATTC# CRL-2647) and
control mouse fibroblasts (ATTC# CRL-2648) were main-
tained at 37°C in 5% CO2 and cultured in DMEM supple-
mented with 10% FBS and 20 μg/mL Gentamycin
(GIBCO). To generate conditioned media, both mouse
fibroblast cell lines were split 1:10 and allowed to grow
for 4 days (approximately to confluency). The media was
removed and sterilized by passing through a 0.2 μm filter.
10 ml of fresh culture media was be added to the cells
which were cultured for another 3 days. The media was
removed, sterilized by passing through a 0.2 μm filter, and
mixed with the first batch of media 1:1.
RNA Isolation and Real-Time PCR
Total RNA was extracted from cells using an acid-phenol
extraction procedure [67], according to the manufac-
turer's instructions (Trizol, Invitrogen, Carlsbad, CA). Rel-
ative levels of mRNA were determined by quantitative
real-time PCR using the Mx4000™ real time PCR system
(Stratagene, La Jolla, CA) and all values were normalized
to the amplification of GAPDH. The PCR primer
sequences are listed in Additional file 2. The assays were
performed using the 1-Step Brilliant® SYBR® Green QRT-
PCR Master Mix Kit (Stratagene) containing 200 nM for-
ward primer, 200 nM reverse primer, and 100 ng total
RNA. The conditions for cDNA synthesis and target
mRNA amplification were performed as follows: 1 cycle of
50°C for 30 min; 1 cycle of 95°C for 10 min; and 35
cycles each of 95°C for 30 s, 55°C for 1 min, and 72°C for
30 s.
Western Blot Analysis
Following 1 week in culture, the supernatant of TERT-
pSUPER and TERT-SFRP1 cells was collected and concen-
trated using the Nanosep 10 K Omega kit (Pall Corpora-
tion, Ann Arbor, MI) according to the manufacturer's
instructions. Protein concentration was quantified using
the BCA™ Protein Assay Kit (Pierce, Rockford, IL). A total
of 100 μg of protein was run on a 10% SDS-Page gel and
transferred to a PVDF membrane. The membrane was
blocked for 45 minutes with 5% milk in tris-buffered
saline containing 0.05% Tween-20 (TBS-T). The primary
antibody [rabbit anti-human SFRP1 (Rockland, Gilberts-
ville, PA)] was diluted 1:200 and incubated overnight at
4°C. The secondary antibody [goat anti-rabbit IgG-HRP
(Santa Cruz Biotechnology, Santa Cruz, CA)] was applied
(1:5000) and incubated for 45 minutes at room tempera-
ture. The blot was washed and developed using a Western
Blot Luminol Reagent (Santa Cruz Biotechnology).
Fluorescent Immunocytochemistry
TERT-pSUPER and TERT-siSFRP1 cells (5 × 104 cells/well)
were plated on glass coverslips in a 24 well plate and
allowed to adhere overnight. The following day, the media
was removed, cells were rinsed with 1× PBS, and fixed inCancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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3.7% formaldehyde for 10 min at room temperature. Next
cells were permeabilized with 0.5% TritonX-100 for min at
4°C followed by 3 15 min washes with PBS:glycine (130
mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2 HPO4, 100 mM
glycine). Cells were then blocked in IF buffer (130 mM
NaCl, 7 mM Na2HPO4, 3.5 mM NaH2 HPO4, 7.7 mM NaN,
0.1% BSA, 0.2% TritonX-100, 0.05% Tween 10) plus 10%
goat serum (GS) for 1–2 hrs and subsequently with 2°
blocking buffer [IF buffer containing 10% GS and 20 μg/ml
goat anti-mouse F(ab')2] for 30–45 min. Rabbit anti-β-cat-
enin (Millipore, Billerica, MA) was diluted 1:500, mouse
anti-E-cadherin (BD Transduction, Mississauga, ON. Can-
ada) was diluted 1:50, and mouse anti-vimentin (clone 9;
Theremoscientific, Waltham, MA) was diluteld 1:50 in 2°
blocking buffer and incubated overnight at 4°C. Unbound
1° antibody was removed by washing 3× in IF buffer for 15
min each and then an anti-rabbit or anti-mouse 2° anti-
body coupled with Alexa Fuor-568 (Molecular Probes, Inv-
itrogen) was diluted 1:500 in IF buffer containing 10% GS
and incubated for 45–60 min. Unbound 2° antibody was
washed as described above. The coverslips were removed
from the wells, mounted onto microscope slides with
Vectashield Mounding Medium for Fluorescence with
DAPI (Vector Laboratories Inc, Burlingame, CA), and
images were captured with a Nikon Eclipse TE2000-U at the
same exposure and gain using Metaview™ software (Uni-
versal Imaging Corporation, Downingtown, PA).
Transient Transfection and Luciferase Assay
A total of 1 × 105 TERT-pSUPER or TERT-siSFRP1 cells/
well were plated in a 24 well plates and were transfected
the following day with 0.8 μg of either Super8xTOPFlash
or Super8XFOPflash as well as 0.08 μg pRL-CMV. After a
6 hour incubation, the media was removed and replaced
with either control medium or Wnt3a medium. Twenty-
four hour after media treatment, cells were washed with
1× PBS and lysed using passive lysis buffer (Promega).
Luciferase activity was detected using the Dual-Luciferase®
reporter assay system (Promega) according to the manu-
facture's instructions and the light output was measured
with a luminometer (MONLIGHT®  1500, Analytical
Luminescence Laboratory, San Diego, CA).
Proliferation Assay
TERT-pSUPER and TERT-siSFRP1 cells (7.5 × 104 cells/
well) were plated in 6-well dishes and the following day,
the media was changed to control medium or Wnt3a
medium containing 1 μCi/ml  3H-Thymidine (Perk-
inElmer, Waltham, MA). Twenty-four hours after the
media change, cells were rinsed with 1× PBS and 10%
trichloroacetic acid (TCA) was be added. The 10% TCA
was removed and cells were washed again with 1× PBS.
Next, cells were incubated in 0.1% SDS/0.1 N NaOH for
5 minutes at room temperature to lyse the cells. Lastly,
200 μl acetic acid and 800 μl of the cell lysate was added
to 5 ml of scintillation and cpm values were collected
using a scintillation counter (Tri-Carb 2900TR, Perk-
inElmer).
Fluorescent Activated Cell Sorting (FACS)
For anoikis studies, 30 mm dishes were coated with 2 ml
of 1% agarose/DMEM, which was allowed to polymerize
creating a barrier that would prevent cellular attachment,
and TERT-pSUPER or TERT-siSFRP1 cells (1.5 × 105 cells/
well) were seeded in 2 ml of growth medium. After 24
hours, the media was collected and cells were pelleted by
centrifugation. The pellet was resuspended in ice-cold 1×
PBS, transferred into a round bottom 12 × 75 mm plastic
culture tube (VWR international, NJ, USA), and incubated
with 1 μg/ml propidium iodine (Invitrogen) in the dark
for 15 minutes at room temperature to stain the dead
cells. The ratio of dead cells/live cells was determined by
flow cytometry (BD FACS Calibur, BD Bioscience, San
Jose, CA).
For cell surface marker analysis, cells were washed once
with PBS and then harvested with 0.05% trypsin/0.025%
EDTA. Detached cells were washed with PBS containing
1% FBS and 1% penicillin/streptomycin (wash buffer),
and resuspended in the wash buffer (106 cells/100 μl).
Combinations of fluorochrome-conjugated monoclonal
antibodies obtained from BD Biosciences against human
CD44 (FITC; cat. #55478) and CD24 (PE; cat. #555428)
and incubated at 4°C in the dark for 30 min. The labeled
cells were washed in wash buffer and immediately ana-
lyzed by flow cytometry (BD FACS Calibur).
Migration and Invasion Assays
For the scratch-wound assay, TERT-pSUPER and TERT-
siSFRP1 cells were plated in 30 mm dishes, allowed to
reach 100% confluence, and a pipette tip was utilized to
generate a wound (scratch) down the center of the plate.
Images of the cells capable of migrating across the scratch
8 hours after the wound were captured with a Nikon
Eclipse TE2000-U using Metaview™ software (Universal
Imaging Corporation). For chamber assays, TERT-pSU-
PER and TERT-siSFRP1 cells (5 × 105 cells/well) were
seeded in serum free media in either BD BioCoat control
chambers or Matrigel™ invasion chambers (BD Bio-
sciences) above media containing 10% FBS. After a 22
hour incubation, chambers were removed and cells were
fixed for 10 min in 10% formalin, stained for 10 min with
10% Crystal Violet, and rinsed 3× with dH20. Non-migrat-
ing/invading cells were removed from the upper surface of
the membrane by scrubbing the insert with a cotton
tipped swab moistened with 1× PBS. The insert was
removed from the chamber with a scalpel, placed on a
microscope slide. Images were captured with an Olympic
BX41 light microscope using SPOTSOFTWARE (Diagnos-
tic Instruments, Inc, Sterling Hights, MI).Cancer Cell International 2009, 9:11 http://www.cancerci.com/content/9/1/11
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Microarray Analysis
Agilent 4X44K human microarrays were performed by the
Genomics Core Facility at University of North Carolina at
Chapel Hill according to the manufacturers Amplification
protocol. Four harvests at 60–80% confluence of the par-
ent 76 N TERT cells were pooled and labeled with Cy3,
while separate harvests (n = 4) of the SFRP1 knockdown
cells were labeled in Cy5. Agilent feature extraction, loess
normalization, and filtering of all spots with signal < 10
dpi was performed prior to supervised analysis. One class
Significance Analysis of Microarrays [68] was used to
identify genes that were significantly altered in knock-
downs relative to parents with a False Detection Rate
(FDR) < 5%.
Statistical Analysis
Results were analyzed using a student's t-test or two-factor
analysis of variance (ANOVA). Post-hoc tests, where
appropriate, were performed by Bonferroni's t test, where
the mean squared error term in the ANOVA table was used
as the point estimate of the pooled variance (Prizm,
GraphPad Software, Inc, San Diego, CA).
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